Sangamo grabs $6.4M partnership for gene-editing drug; Novartis comes clean on actions of employees in 'independent' Diovan studies;

 @FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech

 @JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce

 @RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce

> Following criticisms about conflicts of interest in its ranks, Novartis ($NVS) said on its website that two company employees were involved in what were supposed to be independent clinical trials for its blockbuster Diovan. Article

> Sangamo BioSciences ($SGMO) has scored a $6.4 million award from the California Institute for Regenerative Medicine to develop a potential corrective therapy based on the biotech's gene-editing technology for the blood disorder beta-thalassemia. Release

> QB3 Institute has struck a partnership to open its fifth life sciences incubator to support startups in the Bay Area, targeting a 24,000-square-foot space in the San Francisco's Dogpatch neighborhood. Article

Pharma News

 @FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma

 @EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce

> BRIC markets turning out to be tougher to mine than expected. More

> Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board. Story

> Novartis apologizes over Diovan study as probe shows employee involvement in trials. Article

Medical Device News

 @FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev

 @MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce

 @DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce

> Ethicon study asserts safety of medical-grade polycarbonate devices. Story

> Covidien, Kona Medical trumpet new tech at EuroPCR. More

> Covidien's board approves pharma spinoff. Article

And Finally… Are the folks from Genentech getting a head start on packing for the big ASCO meeting? Video

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.